A comprehensive review of patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease

被引：0
|
作者：
Sapmaz, Aybuke [1 ]
Paik, Annette [2 ]
Henry, Linda [1 ,2 ,3 ]
Younossi, Zobair M. [1 ,2 ,3 ]
机构：
[1] Global NASH Council, Ctr Outcomes Res Liver Dis, 2411 1 St, Washington, DC 20023 USA
[2] Inova Hlth Syst, Beatty Liver & Obes Res Program, Falls Church, VA 22042 USA
[3] Ctr Outcomes Res Liver Dis, Washington, DC 20023 USA
来源：
METABOLISM AND TARGET ORGAN DAMAGE | 2024年 / 4卷 / 04期
关键词：
NAFLD; MAFLD; patient-reported outcome (PRO); quality of life; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; CLINICAL-TRIALS; HEPATITIS-C; FATIGUE; IMPACT; QUESTIONNAIRE; VALIDATION; PERFORMANCE; INSTRUMENT;
D O I：
10.20517/mtod.2024.70
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
of other patient-centric outcomes and provides insights for the healthcare community to develop interventions that could improve both clinical and humanistic outcomes for individuals living with MASLD/MASH.
引用
收藏
页数：11
相关论文
共 50 条
  • [41] Metabolic Dysfunction-Associated Steatotic Liver Disease: An Overview of Pharmacotherapy
    El Hussein, Mohamed
    Favell, Daniel
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2025, 21 (02):
  • [42] Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease
    Cherubini, Alessandro
    Della Torre, Sara
    Pelusi, Serena
    Valenti, Luca
    TRENDS IN MOLECULAR MEDICINE, 2024, 30 (12) : 1126 - 1136
  • [43] Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Scarpellini, Emidio
    Scarcella, Marialaura
    Tack, Jan F.
    Scarlata, Giuseppe Guido Maria
    Zanetti, Michela
    Abenavoli, Ludovico
    ANTIOXIDANTS, 2024, 13 (11)
  • [44] Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Rodriguez, Luis A.
    Schmittdiel, Julie A.
    Liu, Liyan
    Macdonald, Brock A.
    Balasubramanian, Sreepriya
    Chai, Krisna P.
    Seo, Suk I.
    Mukhtar, Nizar
    Levin, Theodore R.
    Saxena, Varun
    JAMA NETWORK OPEN, 2024, 7 (07) : e2421019
  • [45] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    GUT, 2024, 73 (03) : 533 - 540
  • [46] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51
  • [47] Systematic review of exercise for the treatment of pediatric metabolic dysfunction-associated steatotic liver disease
    Smith, Martha R.
    Yu, Elizabeth L.
    Malki, Ghattas J.
    Newton, Kimberly P.
    Goyal, Nidhi P.
    Heskett, Karen M.
    Schwimmer, Jeffrey B.
    PLOS ONE, 2024, 19 (12):
  • [48] Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
    Loomba, Rohit
    Wong, Vincent Wai-Sun
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 150 - 156
  • [49] Chemoprevention of hepatocellular carcinoma associated with metabolic dysfunction-associated steatotic liver disease: an updated review
    Dickinson, Averie
    Dinani, Amreen
    Wegermann, Kara
    HEPATOMA RESEARCH, 2024, 10
  • [50] SYSTEMATIC REVIEW OF EXERCISE FOR THE TREATMENT OF PEDIATRIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
    Smith, Martha
    Yu, Elizabeth
    Malki, Ghattas
    Newton, Kimberly
    Goyal, Nidhi
    Heskett, Karen
    Schwimmer, Jeffrey
    HEPATOLOGY, 2024, 80 : S1949 - S1950
12345